Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer

• Published in: NPJ breast cancer Vol. 3; no. 1; pp. 17 - 8
• Main Authors: Solzak, Jeffrey P., Atale, Rutuja V., Hancock, Bradley A., Sinn, Anthony L., Pollok, Karen E., Jones, David R., Radovich, Milan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.04.2017; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154/555; 631/208/68; 631/67/1347; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer Research; Cell Biology; Human Genetics; Oncology

Triple negative breast cancer accounts for 15–20% of all breast cancer cases, but despite its lower incidence, contributes to a disproportionately higher rate of mortality. As there are currently no Food and Drug Administration-approved targeted agents for triple negative breast cancer, we embarked...